TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.

TRACON Pharmaceuticals Stock Performance

Shares of NASDAQ TCON opened at $0.21 on Wednesday. The company has a market cap of $707,575.00, a P/E ratio of 0.31 and a beta of 1.35. TRACON Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $14.75. The firm’s fifty day moving average is $0.26 and its two-hundred day moving average is $2.09.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The firm had revenue of $0.06 million during the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.